Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
murine BCMA bispecific antibody
- Development stage
- Preclinical
- Lead developer
- Bristol Myers Squibb
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Intraperitoneal, Subcutaneous
01
Overview
The murine BCMA bispecific antibody is a preclinical research tool designed to evaluate the efficacy and immune dynamics of T-cell redirection in mouse models of multiple myeloma, such as the Vk*MYC model. It functions by simultaneously binding to B-cell maturation antigen (BCMA) on malignant plasma cells and the CD3 complex on T cells, thereby facilitating the formation of an immunological synapse and subsequent T-cell mediated lysis of the tumor cells. In research settings supported by Bristol Myers Squibb, this antibody has been utilized in conjunction with intravital imaging to visualize the spatial distribution, expansion, and persistence of CD8+ T cells within the bone marrow microenvironment, providing insights into mechanisms of therapeutic resistance and tumor escape.
- Other names
- murine BCMA x CD3 bispecific antibodymurine BCMA-TCB
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on murine BCMA bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on murine BCMA bispecific antibody.